Q2 2026 iRhythm Holdings, Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: €110 (+2.80%)

Transcript 10-Q8-K

Key Points

Positve

iRhythm Holdings Inc (IRTC) delivered its seventh consecutive quarter of revenue growth above 20%, with Q2 revenue reaching $224.2 million, up 20.1% year-over-year.
The company achieved record profitability, with adjusted EBITDA margin expanding to 19.3% in Q2, an improvement of over 1,000 basis points year-over-year.
iRhythm Holdings Inc (IRTC) announced the acquisition of VitalConnect, which expands its product portfolio into the full MCT market and adds capabilities for hospital monitoring, hospital-to-home programs, and multivital monitoring.
The FDA cleared the company's third-generation algorithm, which is expected to reduce clinical technician review time by up to 50% and generate approximately $100 million in cumulative cost savings over five years.
The company raised its full-year 2026 revenue guidance to $880-$890 million (18-19% growth) and raised its adjusted EBITDA margin guidance to 13-14%.
iRhythm Holdings Inc (IRTC) generated record free cash flow of $37.5 million in Q2 and ended the quarter with a strong cash position of $591.3 million.
The company resolved its outstanding litigation with Baxter for a $50 million settlement, removing a source of uncertainty and allowing management to focus on strategic initiatives.
Final LCDs from Noridian, CGS, and Palmetto provided constructive reimbursement outcomes, clarifying modality-specific coverage without adding access restrictions.

Negative

iRhythm Holdings Inc (IRTC) remains subject to an FDA warning letter, and the timing of its resolution is uncertain and dependent on the agency's review process.
The company experienced a cybersecurity incident in June, which resulted in the exfiltration of certain data, although it reported no material impact on operations or financial results.
The VitalConnect acquisition introduces integration risks, including the need to scale volumes quickly and train a nationwide commercial team, which could divert focus from other initiatives like ZioMCT.
The company's ZioMCT product launch is still pending FDA clearance, and management indicated that VitalConnect's VitalPatch will be the primary commercial focus in the near term, potentially delaying ZioMCT's market entry.
The company expects to incur certain unique items, such as litigation settlement payments and transaction costs, which could impact free cash flow in the near term.
New store contributions to volume growth decreased to 45% from previous quarters, indicating a shift towards same-store growth and potential normalization in new account acquisition.
The company faces potential cost pressures from the broader macro and geopolitical environment, including tariffs, although it does not currently expect a material impact on gross margin.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IRTC.OQ - iRhythm Holdings, Inc
Q2 2026 iRhythm Holdings, Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, everyone. Thank you for joining us and welcome to the iRhythm Holdings, Inc. Q2 2026 Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press *1 to raise your hand. To withdraw your question, press *1 again.

I will now hand the conference over to Lisa Pecora, Senior Vice President, Finance and Investor Relations. Lisa, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for joining iRhythm's second quarter 2026

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.